Beam Therapeutics, Inc. (BEAM)
22.85
-1.18
(-4.91%)
USD |
NASDAQ |
Nov 13, 16:00
22.99
+0.14
(+0.61%)
After-Hours: 19:59
Beam Therapeutics Enterprise Value : 1.686B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 1.686B |
| November 11, 2026 | 1.870B |
| November 10, 2026 | 1.802B |
| November 09, 2026 | 1.995B |
| November 06, 2026 | 1.932B |
| November 05, 2026 | 1.876B |
| November 04, 2026 | 2.075B |
| November 03, 2026 | 1.924B |
| November 02, 2026 | 1.876B |
| October 30, 2026 | 2.017B |
| October 29, 2026 | 2.183B |
| October 28, 2026 | 2.177B |
| October 27, 2026 | 1.776B |
| October 26, 2026 | 1.661B |
| October 23, 2026 | 1.688B |
| October 22, 2026 | 1.741B |
| October 21, 2026 | 1.770B |
| October 20, 2026 | 1.779B |
| October 19, 2026 | 1.702B |
| October 16, 2026 | 1.628B |
| October 15, 2026 | 1.758B |
| October 14, 2026 | 1.646B |
| October 13, 2026 | 1.727B |
| October 12, 2026 | 1.800B |
| October 09, 2026 | 1.858B |
| Date | Value |
|---|---|
| October 08, 2026 | 1.745B |
| October 07, 2026 | 1.762B |
| October 06, 2026 | 1.810B |
| October 05, 2026 | 1.855B |
| October 02, 2026 | 1.734B |
| October 01, 2026 | 1.723B |
| September 30, 2026 | 1.729B |
| September 29, 2026 | 1.626B |
| September 28, 2026 | 1.597B |
| September 25, 2026 | 1.601B |
| September 24, 2026 | 1.641B |
| September 23, 2026 | 1.611B |
| September 22, 2026 | 1.772B |
| September 21, 2026 | 1.703B |
| September 18, 2026 | 1.671B |
| September 17, 2026 | 1.642B |
| September 16, 2026 | 1.480B |
| September 15, 2026 | 1.492B |
| September 14, 2026 | 1.585B |
| September 11, 2026 | 1.572B |
| September 10, 2026 | 1.611B |
| September 09, 2026 | 1.694B |
| September 08, 2026 | 1.865B |
| September 04, 2026 | 2.157B |
| September 03, 2026 | 2.137B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.236B |
| Twist Bioscience Corp. | 7.085B |
| Prime Medicine, Inc. | 720.48M |
| Sarepta Therapeutics, Inc. | 1.891B |
| Q32 Bio, Inc. | -20.82M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -134.40M |
| Revenue (Quarterly) | 0.307M |
| Total Expenses (Quarterly) | 134.71M |
| EPS Diluted (Quarterly) | -1.284 |
| Gross Profit Margin (Quarterly) | -1.67K% |
| Profit Margin (Quarterly) | -43.78K% |
| Earnings Yield | -4.57% |
| Normalized Earnings Yield | -4.449 |